Medicalgorithmics S.A. has received FDA approval in the U.S. for its proprietary next generation system in ECG signal analysis called DeepRhytmAI. It is a cloud-based Artificial Intelligence algorithm that classifies ECG signals. Without excessive human involvement, DeepRhytmAI is able to recognize a wide range of arrhythmia disorders for a more quick and accurate patient diagnosis.

DeepRhytmAI is designed for use with the Company's devices but can be integrated with solutions of other providers, as well. Based on the Company's data, once DeepRhytmAI is integrated with the next generation of PocketECG system (under development) it could cut down the work needed to classify ECG signal by about 50%. DeepRhytmAI will be accessible to business partners who use its devices together with the next generation PocketECG system not earlier than in the second half of 2023.

Medicalgorithmics operates in the industry of advanced telemetry for medicine. The Group provides solutions for cardiac diagnostics, especially in the area of ECG signal analysis. Its services are available in several countries and continents of the world, including North America, Asia, Europe and Australia.